Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | SVP Chemistry&Pharma Sciences | January 22, 2019 | January 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date January 22, 2019 · Filed January 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $15.47 · Expires 2029-01-21 | Direct | 75,000 |
Reported balance
After 2019-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-22 · Grant · Acquired 75,000 · Balance 75,000 F1: This option vests in 48 equal monthly installments commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in 48 equal monthly installments commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2019 Filed Jan 24, 2019 21:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 75,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-19-005135 · doc4.xml · derivative · entry 1 REN PINGDA · CIK 0001635785 · SVP Chemistry&Pharma Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 43,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005614 · doc4.xml · derivative · entry 1 REN PINGDA · CIK 0001635785 · SVP Chemistry&Pharma Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 23, 2017 Filed Jan 25, 2017 22:34 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 55,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-17-005571 · doc4.xml · derivative · entry 1 REN PINGDA · CIK 0001635785 · SVP-Chemistry&Pharma Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-01-22 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.